Publications by authors named "Bai Ou"

Claim this Profile
A
Aberrant lipid metabolism renders an aggressive behavior of T-lymphoblastic lymphoma in a MASH model.
Wei Guo, Xingtong Wang, Guozhen Cui, Emily A S Schmieder, Yonglin Gao, Ou Bai

Oncogene· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.
Yi-Ge Shen, Meng-Meng Ji, Qing Shi, Xiao-Lei Wei, Lei Fan, Hui Zhou, Ou Bai

Mol Biomed· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.
Huijuan Zhong, Shu Cheng, Jie Xiong, Jiayi Chen, Rongji Mu, Ming Hou, Ou Bai, Xin Zhou, Binshen Ouyang

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analysis of primary central nervous system diffuse large B-cell lymphoma.
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Ou Bai

Crit Rev Oncol Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL.
Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Ou Bai

Front Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomedical informatics analysis has revealed a novel hub gene of the HBx in the pathogenesis and progression of DLBCL.
Ying Zhang, Wei Guo, Haotian Wang, Zhumei Zhan, Rui Xing, Ou Bai

iScience· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.
Si-Yuan Chen, Peng-Peng Xu, Ru Feng, Guo-Hui Cui, Li Wang, Ou Bai, Fan Zhou, Hui Zhou, Ke-Shu Zhou

Cancer Commun (Lond)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular heterogeneity of CD30 peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study.
Yu-Jia Huo, Shu Cheng, Hong-Mei Yi, Ting Niu, Lei Fan, Fu-Ling Zhou, Ou Bai

EBioMedicine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.
Haotian Wang, Ying Zhang, Xin Wan, Zhaoxia Li, Ou Bai

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective study on the efficacy of pegfilgrastim-filgrastim combination regimen in the mobilization for autologous stem cell transplantation in lymphoma patients.
Xingtong Wang, Wei Guo, Junna Li, Jia Li, Yangzhi Zhao, Ou Bai

Am J Med Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBx induces chemoresistance in diffuse large B cell lymphoma by inhibiting intrinsic apoptosis via the NF-κB/XIAP pathway.
Zhumei Zhan, Wei Yang, Wei Guo, Xin Wan, Jia Li, Ou Bai

Mol Ther Nucleic Acids· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
Jing Liu, Fenghua Gao, Tingting Zhang, Jiesong Wang, Zhiming Li, Hui Zhou, Ou Bai, Liqun Zou, Shiyong Zhou

Br J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.
Haotian Wang, Ying Zhang, Zhaoxia Li, Ou Bai

Front Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial.
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ou Bai

EClinicalMedicine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018-2022): A real-world, retrospective study.
Zhaoxia Li, Wei Guo, Yangzhi Zhao, Haotian Wang, Jing Guo, Ken H Young, Ou Bai

Cancer Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carcinogenic mechanisms of virus-associated lymphoma.
Ying Zhang, Wei Guo, Zhumei Zhan, Ou Bai

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes.
Wenjie Xiong, Ying Yu, Chunyan Sun, Juan Du, Zhen Cai, Ou Bai

Haematologica· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
Zhumei Zhan, Wei Guo, Xin Wan, Bowen Wang, Jia Li, Ken H Young, Ou Bai

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes with HLX01 (HanliKang), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Hui Zhou

BMC Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the treatment of relapsed/refractory marginal zone lymphoma.
Haotian Wang, Xin Wan, Ying Zhang, Jing Guo, Ou Bai

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.
Zhaoxia Li, Wei Guo, Ou Bai

Front Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supplementary Motor Area Activity Differs in Parkinson's Disease with and without Freezing of Gait.
J Sebastian Marquez, Ronny P Bartsch, Moritz Günther, S M Shafiul Hasan, Or Koren, Ou Bai

Parkinsons Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.
Xin Wan, Ken H Young, Ou Bai

Front Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases.
Anna Wang, Wei Guo, Daniela Damiani, Vikram Sumbly, Gaurav Goyal, Ou Bai

Transl Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis